Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Magnetic resonance-guided laser interstitial thermal therapy for mesial temporal lobe epilepsy (MINE): a single-centre, prospective, randomised, open-label, blinded-endpoint controlled trial protocol in China.

BMJ open·2026

Same author

The Value of Second-Generation Metagenomic Sequencing in the Diagnosis of Respiratory Infections.

Clinical laboratory·2026

Same author

A stochastic agent-based model for simulating tumor-immune dynamics and evaluating therapeutic strategies.

Mathematical biosciences and engineering : MBE·2026

Same author

Mathematical model of tumor-macrophage interactions: Elucidating the tumor-driven macrophage phenotype reprogramming.

Journal of theoretical biology·2026

Same author

Multiscale modeling reveals synergy between CCL19 and PD-1 blockade in reshaping the TNBC microenvironment.

NPJ systems biology and applications·2026

Same author

Material and fabrication factors governing rice seedling growth in seed rope direct seeding systems.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Jan 7, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Decoding Senescence-Driven Heterogeneity in Early-Onset Colorectal Cancer for Prognostic and Therapeutic

Du Cai^1,2,3, Mingru Mai^2,3, Rende Huang^2,3

¹Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China.

|December 28, 2025

Summary

Cellular senescence drives aggressive early-onset colorectal cancer (EOCRC) in patients under 50. A new senescence scoring system (EO-Senscore) predicts treatment response to immunotherapy, chemotherapy, or senolytic drugs.

Keywords:

cellular senescence early‐onset colorectal cancer personalized therapy prognostic model tumor microenvironment

More Related Videos

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Related Experiment Videos

Last Updated: Jan 7, 2026

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Area of Science:

Oncology
Cell Biology
Genomics

Background:

Early-onset colorectal cancer (EOCRC) is aggressive and lacks targeted therapies.
Cellular senescence, a state of stable cell cycle arrest, is implicated in cancer development and progression.

Purpose of the Study:

To investigate the role of cellular senescence in EOCRC malignancy.
To develop a senescence scoring system (EO-Senscore) for precision oncology in EOCRC.

Main Methods:

Multi-omics analysis of 2961 EOCRC patient samples.
Machine learning model development for the EO-Senscore.
In vitro experiments with senolytic drugs.

Main Results:

Cellular senescence is pronounced and varied in EOCRC, independent of chronological age.
Two senescence subtypes identified: low-senescence (favorable prognosis, immunogenic) and high-senescence (aggressive, immunosuppressive).
EO-Senscore accurately stratified patients by prognosis and predicted response to immunotherapy, chemotherapy, and senolytic drugs.

Conclusions:

Cellular senescence is a key driver of EOCRC aggressiveness.
The EO-Senscore offers a quantitative tool for personalized treatment strategies.
Targeting senescence pathways with immunotherapy or senolytic drugs shows promise for EOCRC treatment.